The device uses a brain-computer interface (BCI), which connects a person's nervous system to devices capable of interpreting their brain activity, allowing them to act by the sheer force of their thought. Neuracle's system is aimed at people who have paralysis caused by serious injuries to the spinal cord in the neck. It works by detecting brain signals linked to the intention to move the hand, translating them via software, and sending them to a robotic glove worn by the patient. The robotic glove uses air-powered movement to help the hand open and close, enabling the user to grasp objects.
Eligibility for the device is restricted to adults between the ages of 18 and 60 who have had paralysis for over a year and whose condition has remained stable for at least six months. It is designed for individuals who cannot grip objects with their hands but still retain some movement in their upper arms.
Elon Musk said recently in an X post that his brain implant company Neuralink, which started human trials in 2024, will start 'high-volume production' of BCI devices in 2026.
China has been increasing its investment in brain-computer interface technology in recent years. The country has recently included BCI technology as a national strategic priority and plans to feature it in its upcoming economic planning as a potential driver of future growth.
Globally, companies are racing to bring similar technologies to market. Last year, another brain-computer interface developed by the Chinese company Shanghai NeuroXess drew international attention after a 28-year-old man who had been paralyzed for eight years following a severe spinal cord injury was able to control digital devices using his thoughts five days after receiving the implant in China. In the United States, Elon Musk said recently in an X post that his brain implant company Neuralink, which started human trials in 2024, will start 'high-volume production' of BCI devices in 2026.
Key unknowns remain about the approval and implementation of Neuracle's device. The exact date of the approval and the specific regulatory body in China that granted it have not been disclosed. Additionally, the number of patients who have received or are expected to receive the device, its cost, and whether it will be covered by insurance or government programs are unclear. Long-term efficacy and safety data from clinical trials also await further public release.